METADATA
last updated: 2026-03-06 by BA
file_name: Quad Chart v2 - FloodLAMP (Jan 2022).md
file_date: 2022-01-08
title: Quad Chart v2 - FloodLAMP (Jan 2022)
category: various
subcategory: fl-presentations
tags:
source_file_type: gslide
xfile_type: pptx
gfile_url: https://docs.google.com/presentation/d/1u_Qs33LHnoKvucNNd2IrayJ4TYcxtkxWT44ZY5Hy8-I
xfile_github_download_url: https://raw.githubusercontent.com/FocusOnFoundationsNonprofit/floodlamp-archive-wip/main/various/fl-presentations/Quad%20Chart%20v2%20-%20FloodLAMP%20%28Jan%202022%29.pptx
pdf_gdrive_url: https://drive.google.com/file/d/1YOMiDATjQhI2J0nLTT4IQs69x-g5ezwU
pdf_github_url: https://github.com/FocusOnFoundationsNonprofit/floodlamp-archive-wip/blob/main/various/fl-presentations/Quad%20Chart%20v2%20-%20FloodLAMP%20%28Jan%202022%29.pdf
conversion_input_file_type: pdf
conversion: megaparse
license: CC BY 4.0 - https://creativecommons.org/licenses/by/4.0/
tokens: 1100
words: 712
notes:
summary_short: The FloodLAMP Rapid Molecular Mass Screening Platform brief summarizes a vertically integrated, deployable-in-hours LAMP-based screening system combining turnkey field workflows with a mobile app for program management and pooled collection. It lists near-term deliverables across digital tools, training, QMS, regulatory engagement, sourcing, staffing, and funding, alongside reported performance metrics, pilot deployments with municipal/EMS partners, and scaling needs focused on securing commodity lab equipment and consumables.
CONTENT
FloodLAMP Rapid Molecular Mass Screening Platform
Randy True (randy@floodlamp.bio), FloodLAMP Biotechnologies, PBC
## Upper Left Quadrant
### Solution:
FloodLAMP has developed a vertically integrated platform for rapid molecular disease screening that can quickly scale to massive levels. We've optimized a highly efficient workflow around colorimetric LAMP, and built all the physical and digital components for a turnkey solution that is deployable anywhere in hours.
_Photo: A classroom-style room set up for on-site screening operations, with tables and testing equipment visible._
### Demonstrated Success:
We have commercial deployments in 3 states, soon to be 6+, with **EMS departments and municipalities.** Our programs are very successful and vastly outperforming antigen and lab PCR options. 2 of 3 cities operating FloodLAMP have ramped from testing first responders to mandatory for all employees, multiple times per week.
_Photo: Close-up of a gloved hand handling a rack of labeled sample tubes, suggesting pooled or batch processing._
### Value Proposition:
- Local control over population level serial screening.
- Ideal sensitivity that outperforms antigen on front end and purified PCR on back end of infection.
- Improved health and minimized staffing shortages.
- Multiple flexible configurations including ultra portable.
_Photo: Portable hard case used to transport FloodLAMP testing hardware for field deployment._
## Lower Left Quadrant
### Progress:
- 6,000+ people screened, 8 systems deployed.
- Full FDA EUAs submitted for 2 tests, duplex PCR and colorimetric LAMP, as open source protocol EUAs.
- Pre-EUA submitted for clinical study of pooled home collection w/ FloodLAMP Mobile App, IRB approved.
- FloodLAMP Mobile App available in Apple and Google App stores.
- Key IP filed as PCT, LAMP primers licensed from Harvard.
- Pooled home collection pilot successful with local pre-school, caught 2 families positive, school has moved to mandatory surveillance 2X/week.
### Performance Specs:
- Stanford Clin Eval:
- 90% sensitivity, 100% specificity, 12 cp/uL LoD (LAMP EUA)
- 98% sensitivity, 100% specificity, 3 cp/uL LoD (PCR EUA)
- Real World:
- 100% confirmation of known positives (50+)
- only 1 potential false positive from EMS deployments, no known FN
- Recent case report 12/31: FloodLAMP caught positive but Detect, Lucira, Accula and BinaXNow all missed, confirmed with PCR and BinaX 2 days later
- TAT 40min minimum, 60-75min on batches
### COGS and Pricing:
- Currently quoting $8/pool ($2 pp) kit price (reagents, plastics, collection kits).
- $20/pool ($5 pp) full service screening.
## Upper Right Quadrant
### Key Deliverables/Risks/Issues:
| Section | Description & Status | Deliverable Date |
|---|---|---|
| Digital | Launched digital program management App and assets for collection and administration of surveillance screening. | 9/30/21 |
| Quality System | Implement phase1 of quality management system across deployments. | 1/14/22 |
| Training | Ship async training and onboarding material to certify new testing staff quickly. | 1/21/22 |
| Regulatory | 2nd deprioritization by FDA for open source EUAs. Seeking support from BARD/RADx. | 2/1/21 |
| Sourcing | Strong relationships with key reagent suppliers. Seeking agency support for sourcing key consumables at scale. | 1/28/21 |
| Staffing | 3 FT, 2 PT, many advisors. Hire 10 new FT staff to support high volume roll out. | 1/14/22 |
| Funding | Sufficiently capitalize to secure supply, staff and manage demand fluctuations. | 1/15/22 |
||
## Lower Right Quadrant
### Risks:
The biggest delivery risks are on commodity components such as basic lab equipment (heat block and pipettes) and lab consumables (tips and PCR plates). We have secured nonstandard components (mastermix, primers, controls, swabs) at large volume, and have creative options for standard unsecured components.
### Funding:
FloodLAMP has raised XXX from seed investors, and done over $100k in sales with local government pilot sites.
### Customers:
FloodLAMP has partnered with Cities of Coral Springs and Davie Florida, Sacramento Metropolitan Fire District, City of Bend Fire and Rescue Department to protect their critical human infrastructure with locally controlled testing
### Inventory
| | On Hand | 3 Weeks | 6 Weeks+ |
|---|---|---|---|
| Primers | 450,000 reactions
1.8M tests | 1.25M reactions
5M tests | 5M+ tests weekly |
| Consumables | 50k tests | 500k tests* | 5M+ tests weekly* |
| Equipment | 20 systems | 100 systems | 1,000+ systems |
||
*pending agency supply chain support